An edition of Prescription drug pricing (2011)

Prescription drug pricing

cost and control concerns

  • 0 Ratings
  • 1 Want to read
  • 0 Currently reading
  • 0 Have read
Prescription drug pricing
Jonathan R. Dickson, Amy M. Wo ...
Not in Library

My Reading Lists:

Create a new list

Check-In

×Close
Add an optional check-in date. Check-in dates are used to track yearly reading goals.
Today

  • 0 Ratings
  • 1 Want to read
  • 0 Currently reading
  • 0 Have read

Buy this book

Last edited by LC Bot
March 15, 2012 | History
An edition of Prescription drug pricing (2011)

Prescription drug pricing

cost and control concerns

  • 0 Ratings
  • 1 Want to read
  • 0 Currently reading
  • 0 Have read

This edition doesn't have a description yet. Can you add one?

Publish Date
Language
English
Pages
139

Buy this book

Edition Availability
Cover of: Prescription drug pricing
Prescription drug pricing: cost and control concerns
2011, Nova Science Publishers
in English

Add another edition?

Book Details


Table of Contents

Prescription drugs : trends in usual and customary prices for commonly used drugs / GAO
Lack of therapeutically equivalent drugs and limited competition may contribute to extraordinary price increases / GAO
Overview of approaches to control prescription drug spending in federal programs / Statement of John E. Dicken, Director, Health Care, (GAO)
Opening statement of U.S. Senator Amy Klobuchar, hearing on "At what cost? Egregious price increases in the pharmaceutical drug industry" / statement of Senator Charles E. Schumer, Chairman, Joint Economic Committee, Hearing on "At What Cost? Egregious Price Increases in the Pharmaceutical Drug Industry"
Statement of Madeline M. Carpinelli, Stephen W. Schondelmeyer, Prime Institute, College of Pharmacy, University of Minnesota, before the Joint Economic Committee, hearing on "Extraordinary price increases in the pharmaceutical market"
Testimony of Alan L. Goldbloom, MD, president and CEO, Children's Hospitals and Clinics of Minnesota, before the Joint Economic Committee, hearing on "At what cost? Egregious price increases in the pharmaceutical drug industry"
Testimony of Danielle Foltz, before the Joint Economic Committee, hearing on "At what cost? Egregious price increases in the pharmaceutical drug industry"
Entry threats and pricing in the generic drug industry / Brett Wendling, Steven Tenn.

Edition Notes

Includes bibliographical references and index.

Published in
New York
Series
Health care issues, costs and access, Drug transit and distribution, interception and control

Classifications

Dewey Decimal Class
615/.1
Library of Congress
RS100 .P73 2011

The Physical Object

Pagination
viii, 139 p. :
Number of pages
139

ID Numbers

Open Library
OL25230796M
ISBN 10
1613246390
ISBN 13
9781613246399
LCCN
2011015645
OCLC/WorldCat
713186259

Community Reviews (0)

Feedback?
No community reviews have been submitted for this work.

Lists

This work does not appear on any lists.

History

Download catalog record: RDF / JSON
March 15, 2012 Created by LC Bot import new book